Phio Pharmaceuticals Corp.
PHIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533040
In the last 90 days, Phio Pharmaceuticals Corp. insiders filed 5 open-market purchases and 0 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $662.6K in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Phio Pharmaceuticals Corp. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- 0 vs. Q3 2023
- Shares held
- 506.9K
- +220.1K (+76.8%) vs. Q3 2023
- Total value
- $388.8K
- −$56.7K (−12.7%) vs. Q3 2023
- New holders
- 3
- 5 more added
- Sold out
- 3
- 0 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 24 | $662.6K |
| Q1 2026 | 24 | $815.0K |
| Q4 2025 | 17 | $382.3K |
| Q3 2025 | 11 | $467.4K |
| Q2 2025 | 11 | $387.4K |
| Q1 2025 | 11 | $130.8K |
| Q4 2024 | 11 | $277.4K |
| Q3 2024 | 6 | $98.3K |
| Q2 2024 | 12 | $117.0K |
| Q1 2024 | 10 | $106.1K |
| Q4 2023 | 14 | $388.8K |
| Q3 2023 | 14 | $445.4K |
| Q2 2023 | 13 | $798.3K |
| Q1 2023 | 8 | $219.7K |
| Q4 2022 | 12 | $213.2K |
| Q3 2022 | 15 | $415.0K |
| Q2 2022 | 13 | $551.0K |
| Q1 2022 | 15 | $626.0K |
| Q4 2021 | 18 | $991.0K |
| Q3 2021 | 16 | $1.82M |
| Q2 2021 | 17 | $1.58M |
| Q1 2021 | 16 | $1.34M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Phio Pharmaceuticals Corp.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sabby Management, LLC | 172,693 | $131.2K | 1.16% | +16,654+10.7% | Added |
| Anson Funds Management LP | 157,425 | $119.6K | 0.02% | +157,425 | New |
| Citadel Advisors LLC | 31,843 | $24.2K | 0.00% | +31,843 | New |
| Bank of Montreal | 20,000 | $19.0K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 24,380 | $18.5K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 23,486 | $17.8K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 21,056 | $16.0K | 0.00% | +1,349+6.8% | Added |
| Virtu Financial LLC | 19,044 | $14.0K | 0.00% | +19,044 | New |
| Cetera Investment Advisers | 16,916 | $12.9K | 0.00% | +6,250+58.6% | Added |
| Cambridge Investment Research Advisors, Inc. | 14,233 | $11.0K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 5,713 | $4.34K | 0.00% | +3,708+184.9% | Added |
| Morgan Stanley | 125 | $95 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 19 | $14 | 0.00% | +3+18.8% | Added |
| BlackRock Inc. | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −15,229−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −917−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −4−100.0% | Sold out |